Skip to main content

Table 1 Baseline characteristics of migraine patients (FAS)

From: Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial

Parameters

Treatment group (n = 177)

Control group (n = 180)

P value

sex(Male/Female)

54/123

63/117

0.366

Age(year)

39.70 ± 12.81

38.99 ± 11.56

0.654

weight

59.74 ± 9.22

60.94 ± 10.07

0.301

Course (months)

95.76 ± 86.82

91.61 ± 81.87

0.695

Migraine days

4.02 ± 2.16

4.09 ± 1.73

0.181

Migraine attacks

3.37 ± 1.16

3.53 ± 1.11

0.099

Total duration(h)

31.87 ± 36.47

30.26 ± 27.90

0.936

VAS scores

5.63 ± 1.31

5.63 ± 1.27

0.661

Analgesic consumption(times)

1.34 ± 1.66

1.35 ± 1.87

0.726

Total scores of PRO

34.34 ± 5.82

34.94 ± 5.63

0.189

Headache

12.50 ± 1.983

12.71 ± 1.89

0.237

Somatization symptoms

10.53 ± 2.47

10.50 ± 2.51

0.910

Psychological state

4.71 ± 1.46

4.89 ± 1.49

0.195

Functional status

5.77 ± 1.51

5.92 ± 1.49

0.348

PF

92.91 ± 7.07

92.97 ± 8.08

0.527

RP

63.07 ± 37.51

64.56 ± 37.56

0.257

BP

53.71 ± 13.78

52.97 ± 13.98

0.636

GH

60.91 ± 16.93

61.86 ± 17.19

0.531

VT

72.52 ± 13.87

72.31 ± 14.71

0.781

SF

77.07 ± 13.18

75.24 ± 14.56

0.630

RE

70.42 ± 36.22

64.13 ± 39.73

0.371

MH

72.93 ± 14.41

71.39 ± 15.87

0.766

MCS

73.23 ± 14.83

70.77 ± 17.60

0.620

PCS

67.65 ± 14.31

68.09 ± 14.68

0.596